EpiVax and CUBRC win $1M FDA contract to establish best practices for assessing generic peptide drugs

Chris Bergenheim

10/02/2018

EPIVAX AND CUBRC have been awarded a two-year, $1 million federal contract from the U.S. Food and Drug Administration to establish best practices and procedures for assessing generic peptides and related impurities for immunogenic potential. EpiVax CEO and Chief Science Officer Dr. Anne S. De Groot said generic peptides drugs are a quickly growing market. / PBN FILE PHOTO/MICHAEL SALERNO

PROVIDENCE – EpiVax Inc. and CUBRC Inc. have been awarded a two-year, $1 million federal contract from the U.S. Food and Drug Administration to establish best practices and procedures for assessing generic peptides and related impurities for immunogenic potential, EpiVax announced Tuesday. EpiVax CEO and Chief Science Officer Dr. Anne S. De Groot told PBN…

Register to keep reading or subscribe today and receive unlimited access.
Already a Subscriber?

If you have already logged in and are still seeing this message, please refresh the page as your browser is caching the old content.

Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.